Ossium Health Receives $3.46 Million in Funding
The California Institute of Regenerative Medicine CIRM has awarded Ossium Health, Inc. a $3.46M Clinical Stage Research Program CLIN1 grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease (GVHD). This investment will assist and accelerate pre-clinical and manufacturing … Read more